GoodRx: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, 1.3% a year (statements).
US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt less cash at the end of FY2025 (statements); negative means more cash than debt.
What today's price assumes
A market value of $1.2 B means free cash flow growing -3.5% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.
Revenue grew 1.3% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | -3.7% | -1.2% | 1.3% | 3.8% | 6.3% |
|---|---|---|---|---|---|
| 8.15% | +35% | +67% | +107% | +155% | +214% |
| 9.15% | +14% | +41% | +74% | +113% | +161% |
| 10.15% | -1% | +21% | +49% | +82% | +122% |
| 11.15% | -13% | +6% | +30% | +58% | +92% |
| 12.15% | -23% | -6% | +15% | +39% | +69% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of GoodRx, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Healthcare Information Services
Multiples of its companies with a market value at most 60 days old, times GoodRx's own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | GoodRx | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 1.2× / 1.9× / 6.8× | 1.5× | revenue $797 M | $932 M to $5.4 B | 14 |
| Price to book | 1.2× / 2.2× / 4.9× | 1.9× | book equity $616 M | $733 M to $3.0 B | 14 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
GoodRx's multiples at each month end with a market cap on file, Jan 2021 to Oct 2026, each against its own median.
Price to sales
1.5×Now below its median of 2.6×, in the bottom quarter of its range; range 1.0× to 40.7× over 8 months.
Price to book
1.9×Now below its median of 2.2×, in the bottom quarter of its range; range 1.3× to 14.8× over 7 months.
as of Oct 14, 2026. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 14, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $797 M | $30 M | $168 M | $4 M | $164 M | $233 M | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $792 M | $16 M | $184 M | $1 M | $183 M | $52 M | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $750 M | $-9 M | $138 M | $1 M | $137 M | $-25 M | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $767 M | $-33 M | $147 M | $4 M | $143 M | $-90 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $745 M | $-25 M | $179 M | $5 M | $174 M | $-267 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $551 M | $-294 M | $131 M | $21 M | $111 M | $-288 M | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $1.2 B on Oct 14, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.